Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma

NCT04494113 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04494113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04494113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 8, 2022
Completion date
November 30, 2026
Enrollment
12 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial serous adenocarcinoma